Lavipharm S.A. Logo

Lavipharm S.A.

Develops & distributes Rx/OTC medicines, supplements & cosmetics for key therapeutic areas.

LAVI | AT

Overview

Corporate Details

ISIN(s):
GRS246003008
LEI:
213800USC69CRPRGWJ15
Country:
Greece
Address:
AGIAS MARINAS STR, 19002 PAIANIA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Lavipharm S.A. is an integrated international healthcare company focused on the research, development, manufacturing, marketing, and distribution of pharmaceutical products. The company's portfolio includes prescription (Rx) and over-the-counter (OTC) medicines, as well as food supplements and cosmetics. Lavipharm provides innovative treatment options to healthcare professionals, concentrating on key therapeutic areas such as cardiology, neurology (CNS), urology, oncology, and chronic pain. The company manages the entire value chain, from initial research and development to commercial sales and distribution.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-18 19:39
Interim Report
Οικονομική έκθεση LAVIPHARM Α.Ε. (2025,Εξαμηνιαία,Ενοποιημένη)
Greek (modern) 2.2 MB
2025-09-18 16:50
Earnings Release
ΔΕΛΤΙO ΤΥΠΟΥ ΟΙΚΟΝΟΜΙΚΑ ΑΠΟΤΕΛΕΣΜΑΤΑ Α΄ ΕΞΑΜΗΝΟΥ 2025
Greek (modern) 156.3 KB
2025-09-18 16:50
Earnings Release
FINANCIAL RESULTS PRESS RELEASE FIRST HALF 2025
English 99.2 KB
2025-07-10 09:38
Registration Form
Έντυπο παροχής πληροφοριών Κανονισμού (ΕΕ) 2017/1129 (άρθρ. 1 παρ. 5 η’) αναφορ…
Greek (modern) 216.3 KB
2025-07-09 09:52
Share Issue/Capital Change
Έντυπο παροχής πληροφοριών Κανονισμού (ΕΕ) 2017/1129 (άρθρ. 1 παρ. 4 θ΄) αναφορ…
Greek (modern) 205.1 KB
2025-07-03 18:12
Notice of Dividend Amount
ΓΝΩΣΤΟΠΟΙΗΣΗ ΑΠΟΚΟΠΗΣ ΔΙΚΑΙΩΜΑΤΟΣ ΜΕΡΙΣΜΑΤΟΣ / ΠΛΗΡΩΜΗΣ ΜΕΡΙΣΜΑΤΟΣ/ ΠΡΟΜΕΡΙΣΜΑΤ…
Greek (modern) 555.0 KB
2025-07-03 18:00
Post-Annual General Meeting Information
ΔΕΛΤΙΟ ΤΥΠΟΥ ΓΕΝΙΚΗΣ ΣΥΝΕΛΕΥΣΗΣ
Greek (modern) 123.4 KB
2025-07-03 18:00
Post-Annual General Meeting Information
PRESS RELEASE
English 121.3 KB
2025-07-03 17:35
Post-Annual General Meeting Information
ΑΝΑΚΟΙΝΩΣΗ ΕΠΙΤΡΟΠΗΣ ΕΛΕΓΧΟΥ
Greek (modern) 503.0 KB
2025-07-03 17:17
Board/Management Information
ΓΝΩΣΤΟΠΟΙΗΣΗ ΑΛΛΑΓΗΣ ΣΥΝΘΕΣΗΣ ΔΙΟΙΚΗΤΙΚΟΥ ΣΥΜΒΟΥΛΙΟΥ
Greek (modern) 598.1 KB
2025-07-03 17:05
Post-Annual General Meeting Information
ΑΝΑΚΟΙΝΩΣΗ ΓΙΑ ΤΙΣ ΑΠΟΦΑΣΕΙΣ ΓΕΝΙΚΗΣ ΣΥΝΕΛΕΥΣΗΣ
Greek (modern) 195.1 KB
2025-06-11 16:30
Pre-Annual General Meeting Information
ΠΡΟΣΚΛΗΣΗ ΣΕ ΤΑΚΤΙΚΗ ΓΕΝΙΚΗ ΣΥΝΕΛΕΥΣΗ
Greek (modern) 191.0 KB
2025-05-15 16:19
Earnings Release
Βασικά Οικονομικά Μεγέθη A Τριμήνου 2025
Greek (modern) 118.2 KB
2025-05-15 16:19
Earnings Release
Financial Results Q1 2025
English 92.6 KB
2025-04-24 16:39
Investor Presentation
ΑΝΑΚΟΙΝΩΣΗ ΓΙΑ ΕΝΗΜΕΡΩΣΗ ΕΙΣΗΓΜΕΝΗΣ ΠΡΟΣ ΑΝΑΛΥΤΕΣ
English 1.0 MB

Automate Your Workflow. Get a real-time feed of all Lavipharm S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Lavipharm S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.